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abstract
Aim: VCAM-1 and ICAM-1 are two important members of 
the immunoglobulin gene superfamily of adhesion molecules, 
and their potential role as biomarkers of diagnosis, severity 
and prognosis of cardiovascular disease has been investigated 
in a number of clinical studies. The aim of the present study 
was to determine the relationship between circulating ICAM-
1 and VCAM-1 levels and aortic stiffness in patients referred 
for echocardiographic examination. 
Methods: Aortic distensibility was determined by echocar-
diography using systolic and diastolic aortic diameters in 63 
consecutive patients referred for echocardiography. Venous 
samples were collected in the morning after a 12-hour over-
night fast, and serum concentrations of ICAM-1 and VCAM-1 
were measured using commercial enzyme immunoassay kits.
Results: Data of a total of 63 participants (mean age 55.6 ± 
10.5 years, 31 male) were included in the study. Circulating 
levels of adhesion molecules were VCAM-1: 12.604 ± 3.904 
ng/ml and ICAM-1: 45.417 ± 31.429 ng/ml. We were unable 
to demonstrate any correlation between indices of aortic stiff-
ness and VCAM-1 and ICAM-1 levels.
Conclusion: The role of soluble adhesion molecules in cardio-
vascular disease has not been fully established and clinical 
studies show inconsistent results. Our results indicate that 
levels of circulating adhesion molecules cannot be used as 
markers of aortic stiffness in patients.
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Damage to or stimulation of  the endothelium leads 
to the increased expression and release of molecules that 
trigger leukocyte homing, adhesion and migration into the 
subendothelial space, which are fundamental stages of the 
development and progression of atherosclerosis.1 Among these, 
adhesion molecules play a key role. Adhesion molecules are 
substances that mediate the interaction between cells, their 
extracellular matrices and endothelial surfaces. They function as 
receptors that trigger intracellular pathways and participate in 
the control of vital processes.2 
Once expressed on the endothelial surface, soluble forms of 
adhesion molecules may be found in the circulation, released 
either via shedding or proteolytic cleavage, and are considered 
markers of increased expression of membrane-bound adhesion 
molecules.3-5 Vascular cell adhesion molecule 1 (VCAM-1) and 
intercellular adhesion molecule 1 (ICAM-1) are two important 
members of the immunoglobulin gene superfamily of adhesion 
molecules and their potential role as biomarkers of diagnosis, 
severity and prognosis of  cardiovascular disease has been 
investigated in a number of clinical studies.6 
Decreased arterial compliance is one of the earliest signs 
of adverse structural and functional changes within the vessel 
wall.7 Increased arterial stiffness represents a physiological 
aspect of ageing, however, this process can be accelerated 
by cardiovascular risk factors, and has been shown to be an 
independent predictor of cardiovascular morbidity and all-cause 
mortality in various populations.8-10 
Although studies have also demonstrated that increased 
arterial stiffness is associated with inflammation, data on the 
association between aortic distensibility and soluble adhesion 
molecules are sparse.11 The purpose of the present study was 
to determine the relationship between circulating ICAM-1 and 
VCAM-1 levels as inflammatory markers, and aortic stiffness in 
patients referred for echocardiographic examination. 
methods
Sixty-three consecutive patients who were referred for 
echocardiography were included in the study. Patients with renal 
or hepatic failure, known infectious or inflammatory disease, 
acute illness, moderate-to-severe valvular dysfunction, aortic 
dissection or other aortic disease, or poor acoustic quality were 
excluded. The study was approved by our local ethics committee, 
and written informed consent was obtained from each participant.
Aortic stiffness measurements were performed on the subjects 
in the left lateral decubitus position with echocardiography, 
using a Vivid 7 Doppler echocardiographic unit (GE Vingmed 
Ultrasound, Horten, Norway) with a 2.5-MHz probe. The aortic 
diameter was recorded by M-mode echocardiography at a level 
of 3 cm above the aortic valve. 
Internal aortic diameters were measured by means of a caliper 
in systole and diastole as the distance between the trailing edge 
of the anterior aortic wall and the leading edge of the posterior 
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aortic wall. Aortic systolic (AoS) diameter was measured at the 
time of full opening of the aortic valve, and diastolic (AoD) 
diameter was measured at the peak of QRS. Three consecutive 
beats were measured routinely and averaged. 
Systolic and diastolic blood pressures were measured 
simultaneously at the brachial artery by sphygmomanometry. 
Pulse pressure was calculated as systolic minus diastolic blood 
pressure. 
The percentage change of the aortic root Ao (%) was 
calculated to obtain the aortic strain:
Ao (%) =  
100 × (AoS − AoD)
  ________________AoD 
Other indices of the aortic elastic properties were measured. 
Aortic distensibility index (cm-2 dyn-1 10-6) 
=  
2 × (systolic diameter – diastolic diameter)
    _________________________________  (diastolic diameter) × (pulse pressure)  
The aortic stiffness index β =  ln(SBP/DBP)  _______________  (AoS−AoD)/AoD
All venous samples were collected in the morning after a 12-hour 
overnight fast, for biochemical analyses. The blood samples were 
centrifuged at 4 000 rpm at room temperature for 5 min, and 
the plasma was frozen at –20°C until measurement of adhesion 
molecules. Serum concentrations of ICAM-1, and VCAM-1 
were measured using commercial enzyme immunoassay kits 
(E-BIOSCIENCE, San Diego, USA), as instructed by the 
manufacturer.
Statistical analysis
All data analyses were performed with the SPSS (Statistical 
Package for Social Sciences) for Windows 17.0 computer 
program (SPSS Inc. Chicago, IL, USA). Data were expressed 
as mean ± standard deviation. After testing for normality with 
the Shapiro–Wilk test, continuous parameters were analysed 
with non-parametric tests. The relationship between levels of 
circulating adhesion molecules and aortic stiffness was assessed 
by Spearman’s test. Since preliminary analysis did not reveal 
significant interactions with cellular adhesion molecules, we did 
not run models stratified by risk factors for aortic stiffness. A 
p-value of < 0.05 was accepted as significant.
results
Data from a total of 63 participants (mean age 55.6 ± 10.58 years, 
31 male) were included in the study. The baseline characteristics 
of the study population are summarised in Table 1. Circulating 
levels of adhesion molecules were VCAM-1: 12.604 ± 3.904 ng/
ml and ICAM-1: 45.417 ± 31.429 ng/ml. Aortic strain was 6.210 
± 2.253%, stiffness index was calculated as 10.423 ± 5.350 and 
distensibility as 2.354 ± 0.993 × 10-3 /KPa (Table 2). We were 
unable to demonstrate any correlation between the indices of 
aortic stiffness and CAM-1 and ICAM-1 levels (Table 3).
Discussion 
The potential role of soluble adhesion molecules as biomarkers of 
diagnosis, severity and prognosis of cardiovascular disease have 
been investigated in a number of clinical studies. However, these 
studies have found heterogeneous results. Ridker et al. reported 
a significant association between increasing concentrations of 
sICAM-1 and the risk of future myocardial infarction, especially 
among participants with baseline sICAM-1 concentrations in 
the highest quartile.12 
Blankenberg et al. found that VCAM-1, ICAM-1 and 
E-selectin were significantly related to future cardiovascular 
death in 2.7 years’ mean follow up of a prospective cohort of 
1 245 patients.3 Moreover, of all the inflammatory markers 
evaluated, VCAM-1 levels revealed the strongest association 
with future death, and added predictive value to the classic 
risk factors and high-sensitivity C-reactive protein (CRP) in 
determining the risk for future cardiovascular death. 
In a prospective, nested, case–control study, median levels 
of sICAM-1 but not sVCAM-1 were significantly higher at 
baseline among men who developed peripheral arterial disease 
(PAD) during a nine-year follow-up period.13 In the study by 
Hwang et al., E-selectin and ICAM-1 levels were significantly 
increased in patients with coronary heart disease (CHD) and 
carotid artery atherosclerosis compared with the control subjects. 
However, levels of VCAM-1 were not significantly different 
among patients in these groups.14 
In contrast to these findings, in a long-term, community-
based study, Malik et al. assessed the predictive ability of 
baseline serum concentrations of soluble adhesion molecules 
for fatal and non-fatal CHD. They found no strong association 
of these adhesion molecules with CHD risk. Furthermore, they 
reinforced their findings with a meta-analysis of previously 
published prospective studies.15 
table 1. Baseline characteristics of the patients
Characteristics Number (%)
Age (years) 55.6 ± 10.5
Males 31 (49.2) 
Smoking 6 (9.5)
Hypertension 31 (49.2)
Diabetes mellitus 14 (22.2)
Hyperlipidaemia 11(17.5)
Coronary artery disease 18 (25.6)
table 2. serum vCam and iCam levels and  
indices of aortic stiffness
Variables Mean ± SD (n = 63)
VCAM (ng/ml) 12.604 ± 3.904
ICAM (ng/ml) 45.417 ± 31.429
Aortic strain (%) 6.210 ± 2.253
Stiffness index (β) 10.423 ± 5.350
Distensibility (× 10-3/KPa) 2.354 ± 0.993
table 3. Correlation between aortic strain, stiffness index, 
distensibility and adhesion molecules
Variables VCAM (ng/ml) ICAM (ng/ml)
r p r p
Aortic strain (%) –0.030 0.813 0.061 0.634
Stiffness index (β) 0.038 0.768 –0.095 0.458
Distensibility (× 10-3/KPa) –0.026 0.839 0.097 0.449
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Whether soluble adhesion molecules are increased in 
subclinical cardiovascular disease has been investigated in 
several studies. In a sample from the Monitoring Trends in 
and Determinants in Cardiovascular Disease (MONICA) trial, 
despite sICAM-1 levels being independently associated with 
the risk of having at least one carotid or femoral plaque, no 
significant association was found with carotid intima–media 
thickness (CIMT).16 Similarly, Amar et al. showed interleukin-6 
and ICAM levels were associated with stable atherosclerotic 
plaque but not with IMT.17 
In a prospective study by Gross et al., higher sICAM1 levels 
were associated significantly and in a graded fashion with 
common CIMT in participants with advanced plaque.18 The 
study indicated an early (mean age 40 years) involvement of 
sCAM1 in the development of atherosclerosis, independent of 
traditional cardiovascular risk factors and CRP levels. Moreover, 
no association was found in patients with low total burden of 
atherosclerosis. 
Our results are in alignment with these studies. In consecutive 
patients referred for echocardiographic examination, we found 
no association between adhesion molecules and aortic stiffness, 
which is a predictor of cardiovascular disease.
Despite all these studies, the role of  soluble adhesion 
molecules in cardiovascular disease has not been fully established 
and clinical studies show inconsistent results. There are some 
possible explanations for this inconsistency. First, vascular 
endothelial and smooth muscle cells express VCAM-1, while 
ICAM-1 expression is not limited to these cells and is expressed 
in many cells, including haematopoietic cells and fibroblasts.3 
Therefore, VCAM-1 may be a marker of plaque burden or 
activity, whereas ICAM-1 may be a marker of low-grade 
inflammation. Some authors have suggested that ICAM-1 is 
predictive in initially healthy people and VCAM-1 in patients 
with atherosclerosis.3 
Second, levels of soluble adhesion molecules are influenced by 
age, smoking status, diabetes and other inflammatory conditions, 
and even with exercise or changes in arterial pressure.19,20 
Moreover, there is a lack of knowledge of which cellular and 
molecular factors determine the levels of adhesion molecules, 
since VCAM and ICAM, like other inflammatory molecules, 
may have regulations at many levels.6 
Aortic stiffness is an independent predictor of cardiovascular 
risk. Arterial stiffening is a physiological aspect of ageing 
and is the result of the joint effects of adhesion molecules, 
integrins, metalloproteinases, the renin–angiotension system, 
and inflammation of  cellular components (endothelium, 
vascular smooth muscle, fibroblasts and matrix components) on 
the structural and functional properties of the artery.21 Indeed, 
recent studies have shown the importance of inflammation in 
arterial stiffening. Increased levels of inflammatory markers 
have been associated with arterial stiffness in various groups, 
including healthy subjects, hypertensives, and community-based 
groups.21-25 
In the study of Bussel et al., biomarkers of endothelial 
dysfunction and low-grade inflammation, including adhesion 
molecules, were associated with greater arterial stiffness 
over a six-year period.26 A causative effect of acute systemic 
inflammation on increasing large-artery stiffness and decrease 
in wave reflections was also shown in patients receiving 
vaccinations.27 
Several mechanisms may explain the link between arterial 
stiffness and inflammation. First, degradation of the elastin 
and collagen of the vessel wall may be increased by activation 
of  matrix metalloproteinases, which may be mediated by 
increased levels of inflammatory mediators, including adhesion 
molecules.11 Inflammation may also provoke fibrosis and smooth 
muscle proliferation, which would subsequently cause arterial 
stiffness.11 
Another possible explanation is the major role of  the 
endothelium in arterial stiffness. Inflammation causes endothelial 
dysfunction and alters arterial distensibility by impairing the 
production of  vasodilatory factors.27 One last, speculative 
explanation could be arterial stiffness causing inflammation, 
since elevated pulse pressure and increased shear stress may 
stimulate inflammation and increase the expression of adhesion 
molecules.20,22,28 
Conclusion
We were unable to find a significant correlation between aortic 
stiffness and circulating adhesion molecules (VCAM-1 and 
ICAM-1). Possible causes of this finding have been discussed 
above. However, other factors may have affected the results. 
The mean age in our study was 55.6 ± 10.5 years. Since arterial 
stiffening typically occurs after the age of 60 years, our study 
population represented a relatively young population.26 Second, 
arterial stiffening is not a uniform condition in all arterial 
systems, and aortic distensibility is a local measure of arterial 
stiffness.22 Third, levels of adhesion molecules were measured 
only once, and they may be subject to intra-individual variability. 
The small study size is another limitation of this study. 
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